AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20972608 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening intervention group
Number of subjects: 0
Study 20972608 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 19472307 — intervention group
Group type: EXPERIMENTAL
Intervention: Selection criteria for working correlation structures in GEE analysis
Number of subjects: 0
Study 19472307 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-based and sandwich-based estimator of covariance matrix
Number of subjects: 0
Study 19472307 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted error sum of squares minimization
Number of subjects: 0
Study 19472307 — intervention group
Group type: EXPERIMENTAL
Intervention: Rule out criteria for estimated correlation parameters
Number of subjects: 0
Study 19472307 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive definiteness of estimated correlation structure
Number of subjects: 0
Study 17290041 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored asthma management program
Number of subjects: 314
Study 17290041 — intervention group
Group type: COMPARATOR
Intervention: Generic asthma websites (control)
Number of subjects: 314
Study 15549973 — intervention group
Group type: EXPERIMENTAL
Intervention: Magill position (a pillow under the occiput and the head extended)
Number of subjects: 21
Study 15549973 — intervention group
Group type: COMPARATOR
Intervention: Manual in‐line position (without a pillow under the occiput)
Number of subjects: 21
Study 12115394 — intervention group
Group type: EXPERIMENTAL
Intervention: L-758,298 100 mg i.v. + dexamethasone 20 mg i.v. + cisplatin >or= 70 mg/m(2) + MK-869 300 mg orally on Days 2-5
Number of subjects: 177
Study 12115394 — intervention group
Group type: EXPERIMENTAL
Intervention: L-758,298 100 mg i.v. + dexamethasone 20 mg i.v. + cisplatin >or= 70 mg/m(2) + placebo on Days 2-5
Number of subjects: 177
Study 12115394 — intervention group
Group type: COMPARATOR
Intervention: ondansetron 32 mg i.v. + dexamethasone 20 mg i.v. + cisplatin >or= 70 mg/m(2) + placebo on Days 2-5
Number of subjects: 177
Study 10470656 — intervention group
Group type: EXPERIMENTAL
Intervention: 5'‐DFUR (1200 mg/day) administered for more than 5 days before operation
Number of subjects: 46
Study 10470656 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preoperative chemotherapy)
Number of subjects: 46
Study 8682234 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mcg/Kg of atropine in 60 seconds (Group 1)
Number of subjects: 100
Study 8682234 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mcg/Kg of atropine in 120 seconds (Group 2)
Number of subjects: 100
Study 8682234 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mcg/Kg of atropine in 120 seconds (Group 3)
Number of subjects: 100
Study 8682234 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mcg/Kg of atropine in 120 seconds (Group 4, with full-dose oral beta-blocker therapy)
Number of subjects: 100
Study 8682234 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine effect on HR and R-R interval in resting conditions (60 patients, 15 from each group)
Number of subjects: 100
Study 2243886 — intervention group
Group type: EXPERIMENTAL
Intervention: DMI plus propranolol
Number of subjects: 16
Study 2243886 — intervention group
Group type: COMPARATOR
Intervention: DMI
Number of subjects: 16
Study 352473 — intervention group
Group type: EXPERIMENTAL
Intervention: Day care (discharged directly home)
Number of subjects: 360
Study 352473 — intervention group
Group type: COMPARATOR
Intervention: Convalescent hospital (48 hours)
Number of subjects: 360
Study 352473 — intervention group
Group type: COMPARATOR
Intervention: Acute ward (48 hours)
Number of subjects: 360
Study 31901783 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy using a frozen glove (FG) for 60 minutes
Number of subjects: 38
Study 31901783 — intervention group
Group type: COMPARATOR
Intervention: Compression therapy using a surgical glove (SG) for 90 minutes
Number of subjects: 38
Study 31152672 — intervention group
Group type: EXPERIMENTAL
Intervention: Green lentil chili (61.8 g)
Number of subjects: 24
Study 31152672 — intervention group
Group type: COMPARATOR
Intervention: Red lentil chili (54 g)
Number of subjects: 24
Study 31152672 — intervention group
Group type: COMPARATOR
Intervention: Rice chili
Number of subjects: 24
Study 31152672 — intervention group
Group type: COMPARATOR
Intervention: Muffin treatments (wheat replaced with lentils)
Number of subjects: 24
Study 28158893 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (phytosomal form; 1000 mg/day in 2 divided doses)
Number of subjects: 102
Study 25583274 — intervention group
Group type: EXPERIMENTAL
Intervention: Overground simulation
Number of subjects: 19
Study 25583274 — intervention group
Group type: COMPARATOR
Intervention: Treadmill simulation
Number of subjects: 19
Study 25583274 — intervention group
Group type: EXPERIMENTAL
Intervention: Both simulations
Number of subjects: 19
Study 23865947 — intervention group
Group type: EXPERIMENTAL
Intervention: Crisis postcard intervention
Number of subjects: 761
Study 23865947 — intervention group
Group type: COMPARATOR
Intervention: Control group (no postcard intervention)
Number of subjects: 761
Study 21854150 — intervention group
Group type: EXPERIMENTAL
Intervention: UpToDate
Number of subjects: 112
Study 21854150 — intervention group
Group type: EXPERIMENTAL
Intervention: First Consult
Number of subjects: 112
Study 21854150 — intervention group
Group type: EXPERIMENTAL
Intervention: ACP PIER
Number of subjects: 112
Study 21854150 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential Evidence Plus
Number of subjects: 112
Study 19228872 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ(10) supplementation (200 mg/day)
Number of subjects: 23
Study 19228872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 17454335 — intervention group
Group type: EXPERIMENTAL
Intervention: Home environmental assessment
Number of subjects: 177
Study 15260084 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg of oral tizanidine as premedication 60 minutes before arrival in the operating room
Number of subjects: 40
Study 15260084 — intervention group
Group type: COMPARATOR
Intervention: Placebo 60 minutes before arrival in the operating room
Number of subjects: 40
Study 11784459 — intervention group
Group type: EXPERIMENTAL
Intervention: Happy mood condition
Number of subjects: 120
Study 11784459 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral mood condition
Number of subjects: 120
Study 11784459 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed mood condition
Number of subjects: 120
Study 11784459 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular gamblers
Number of subjects: 120
Study 11784459 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular gamblers (losing)
Number of subjects: 120
Study 11784459 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular gamblers (winning)
Number of subjects: 120
Study 11784459 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-regular gamblers
Number of subjects: 120
Study 9175566 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril (n = 10)
Number of subjects: 26
Study 9175566 — intervention group
Group type: EXPERIMENTAL
Intervention: Minoxidil combined with a diuretic (n = 10)
Number of subjects: 26
Study 9175566 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril + Minoxidil (n = 6)
Number of subjects: 26
Study 1494770 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled terbutaline 5 mg
Number of subjects: 20
Study 2858710 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg dipyridamole and 150 mg aspirin daily from 3 months' gestation onwards (group A)
Number of subjects: 102
Study 2858710 — intervention group
Group type: COMPARATOR
Intervention: Control group (group B, no treatment)
Number of subjects: 102
Study 31425580 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg
Number of subjects: 377
Study 31425580 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 377
Study 29701072 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy with Ologen
Number of subjects: 0
Study 29701072 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy with Mitomycin C
Number of subjects: 0
Study 29090661 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy plus patent foramen ovale closure (with GORE® HELEX® Septal Occluder or GORE® CARDIOFORM Septal Occluder)
Number of subjects: 664
Study 29090661 — intervention group
Group type: COMPARATOR
Intervention: Antiplatelet therapy alone
Number of subjects: 664
Study 26009785 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized normative feedback (PNF) intervention
Number of subjects: 252
Study 26009785 — intervention group
Group type: COMPARATOR
Intervention: Attention-control feedback
Number of subjects: 252
Study 23747481 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaniprevir 125 mg qd
Number of subjects: 40
Study 23747481 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaniprevir 600 mg qd
Number of subjects: 40
Study 23747481 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaniprevir 25 mg bid
Number of subjects: 40
Study 23747481 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaniprevir 75 mg bid
Number of subjects: 40
Study 23747481 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaniprevir 250 mg bid
Number of subjects: 40
Study 23747481 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaniprevir 500 mg bid
Number of subjects: 40
Study 23747481 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaniprevir 700 mg bid
Number of subjects: 40
Study 23747481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 20736851 — intervention group
Group type: EXPERIMENTAL
Intervention: ACDF with PCB cage-plate system
Number of subjects: 52
Study 20736851 — intervention group
Group type: COMPARATOR
Intervention: Laminoplasty
Number of subjects: 52
Study 19243603 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (6 months)
Number of subjects: 45
Study 19243603 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 45
Study 17285226 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 13
Study 17285226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 15163774 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 percent albumin
Number of subjects: 6997
Study 15163774 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 6997
Study 11398777 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraluminal papaverine application
Number of subjects: 150
Study 11398777 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical papaverine application
Number of subjects: 150
Study 11398777 — intervention group
Group type: EXPERIMENTAL
Intervention: Periarterial papaverine application
Number of subjects: 150
Study 9424060 — intervention group
Group type: EXPERIMENTAL
Intervention: Orderly electrocardiographic limb lead display
Number of subjects: 83
Study 9424060 — intervention group
Group type: COMPARATOR
Intervention: Classical electrocardiographic limb lead display
Number of subjects: 83
Study 8261557 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based maternal record (HBMR)
Number of subjects: 0
Study 3529917 — intervention group
Group type: EXPERIMENTAL
Intervention: Canned baked beans
Number of subjects: 6
Study 3529917 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-cooked (boiled) baked beans
Number of subjects: 6
Study 3529917 — intervention group
Group type: EXPERIMENTAL
Intervention: D-glucose
Number of subjects: 6
Study 2514152 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic gas inhalation (HC: FIO2 is 16.0% in N2)
Number of subjects: 12
Study 2514152 — intervention group
Group type: COMPARATOR
Intervention: Normoxic conditions (NC: FIO2 is 20.9%; i.e., air)
Number of subjects: 12
Study 31913324 — intervention group
Group type: EXPERIMENTAL
Intervention: H‐HOPE intervention
Number of subjects: 121
Study 31913324 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 121
Study 31626644 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically determined serum urate levels
Number of subjects: 339256
Study 28712103 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided interscalene brachial plexus block (IBPB) with 20 mL of 0.5% ropivacaine (group U)
Number of subjects: 106
Study 28712103 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral nerve stimulation (PNS)‐confirmed IBPB with 20 mL of 0.5% ropivacaine (group N)
Number of subjects: 106
Study 28712103 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided, PNS‐confirmed IBPB (dual guidance) with 20 mL of 0.5% ropivacaine (group NU)
Number of subjects: 106
Study 24722769 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive medical nutrition therapy (IMNT)
Number of subjects: 78
Study 24722769 — intervention group
Group type: COMPARATOR
Intervention: Standard nutrition support care (SNSC)
Number of subjects: 78
Study 23695772 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren (150 mg daily for 2 weeks, then increased to maximum daily dose for 4 weeks)
Number of subjects: 38
Study 23695772 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (5 mg daily for 2 weeks, then increased to maximum daily dose for 4 weeks)
Number of subjects: 38
Study 22080023 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc levels at 137, 309, and 655 mg/kg
Number of subjects: 720
Study 22080023 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine levels at 0.560, 0.612, 0.677, 0.749, and 0.851%
Number of subjects: 720
Study 19097942 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 microg/kg desmoteplase
Number of subjects: 193
Study 19097942 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 microg/kg desmoteplase
Number of subjects: 193
Study 19097942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study 16490951 — intervention group
Group type: EXPERIMENTAL
Intervention: Citicoline 1 g/12 h for 2 weeks (orally or intravenously)
Number of subjects: 38
Study 16490951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 14610756 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide
Number of subjects: 0
Study 14610756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10868869 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 5487
Study 10868869 — intervention group
Group type: COMPARATOR
Intervention: Control (nondiabetic patients without baseline proteinuria)
Number of subjects: 5487
Study 9185396 — intervention group
Group type: EXPERIMENTAL
Intervention: Initiating Ovrette at six weeks postpartum
Number of subjects: 0
Study 9185396 — intervention group
Group type: COMPARATOR
Intervention: Initiating Ovrette at return of menses or 6 months postpartum
Number of subjects: 0
Study 1545000 — intervention group
Group type: EXPERIMENTAL
Intervention: Retroperitoneal (RP) approach
Number of subjects: 27
Study 1545000 — intervention group
Group type: COMPARATOR
Intervention: Transperitoneal (TP) approach
Number of subjects: 27
Study 3885316 — intervention group
Group type: EXPERIMENTAL
Intervention: Iohexol
Number of subjects: 0
Study 3885316 — intervention group
Group type: COMPARATOR
Intervention: Diatrizoate
Number of subjects: 0
Study 29574126 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided biliary drainage (EUS-BD)
Number of subjects: 67
Study 29574126 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic retrograde cholangiopancreatography (ERCP)
Number of subjects: 67
Study 27838224 — intervention group
Group type: EXPERIMENTAL
Intervention: Vismodegib (150 mg/day)
Number of subjects: 41
Study 27838224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 27838224 — intervention group
Group type: EXPERIMENTAL
Intervention: Vismodegib (after crossover from placebo)
Number of subjects: 41
Study 27838224 — intervention group
Group type: COMPARATOR
Intervention: Placebo (initial assignment)
Number of subjects: 41
Study 27838224 — intervention group
Group type: EXPERIMENTAL
Intervention: Vismodegib (continuous dosing)
Number of subjects: 41
Study 27838224 — intervention group
Group type: EXPERIMENTAL
Intervention: Vismodegib (interrupted dosing)
Number of subjects: 41
Study 25040354 — intervention group
Group type: EXPERIMENTAL
Intervention: Early placement (Ea)
Number of subjects: 63
Study 25040354 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed placement (De)
Number of subjects: 63
Study 25040354 — intervention group
Group type: EXPERIMENTAL
Intervention: Late placement (La)
Number of subjects: 63
Study 22098444 — intervention group
Group type: EXPERIMENTAL
Intervention: TGD 300 mg/day
Number of subjects: 0
Study 22098444 — intervention group
Group type: EXPERIMENTAL
Intervention: TGD 900 mg/day
Number of subjects: 0
Study 22098444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20845295 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg sublingual isosorbide dinitrate (ISDN)
Number of subjects: 80
Study 20845295 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 18431738 — intervention group
Group type: EXPERIMENTAL
Intervention: 1950 MHz UMTS (SAR 0.1 and 1 W/kg)
Number of subjects: 15
Study 18431738 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed 900 MHz GSM (1 W/kg)
Number of subjects: 15
Study 18431738 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 15
Study 15758007 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer alert program
Number of subjects: 2506
Study 11133742 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic BMT
Number of subjects: 652
Study 11133742 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous BMT
Number of subjects: 652
Study 11133742 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 652
Study 10366992 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine HCl 10 mg
Number of subjects: 12
Study 10366992 — intervention group
Group type: COMPARATOR
Intervention: Triazolam 0.125 mg
Number of subjects: 12
Study 10366992 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine HCl 10 mg with triazolam 0.125 mg
Number of subjects: 12
Study 8575984 — intervention group
Group type: EXPERIMENTAL
Intervention: Yeast-rich selenium (200 micrograms Se/day for 12 weeks)
Number of subjects: 33
Study 8575984 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium selenite (200 micrograms Se/day for 12 weeks)
Number of subjects: 33
Study 8575984 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 33
Study 2471894 — intervention group
Group type: COMPARATOR
Intervention: Oxprenolol (monotherapy)
Number of subjects: 120
Study 2471894 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone (monotherapy)
Number of subjects: 120
Study 2471894 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of oxprenolol and chlorthalidone
Number of subjects: 120
Study 1201766 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin 160 ng/min. (INS)
Number of subjects: 0
Study 1201766 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin 160 ng/min. (INS) + Secretin 12 ng/min. (SEC)
Number of subjects: 0
Study 1201766 — intervention group
Group type: COMPARATOR
Intervention: Secretin 12 ng/min. (SEC)
Number of subjects: 0
Study 31765269 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-Incision Robotic Colectomy (SIRC)
Number of subjects: 40
Study 31765269 — intervention group
Group type: COMPARATOR
Intervention: Multiport Robotic Colectomy (MPRC)
Number of subjects: 40
Study 31239690 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced recovery after surgery (ERAS)
Number of subjects: 74
Study 31239690 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 74
Study 28894074 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastery learning program for nursing skills
Number of subjects: 50
Study 28894074 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 50
Study 26385928 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational materials on the rationale behind using financial incentives for smoking cessation during pregnancy
Number of subjects: 166
Study 26385928 — intervention group
Group type: COMPARATOR
Intervention: Educational materials on car safety for pregnant women and young children
Number of subjects: 166
Study 25111136 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound (EUS) and endoscopic deep biopsy using the ESD technique (40 patients)
Number of subjects: 68
Study 25111136 — intervention group
Group type: COMPARATOR
Intervention: Surgical resection after EUS without obtaining preoperative pathological diagnosis (28 patients)
Number of subjects: 68
Study 22547592 — intervention group
Group type: EXPERIMENTAL
Intervention: Phased ipilimumab
Number of subjects: 204
Study 22547592 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent ipilimumab
Number of subjects: 204
Study 22547592 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 204
Study 19276664 — intervention group
Group type: EXPERIMENTAL
Intervention: RIX4414 vaccine (n = 182)
Number of subjects: 363
Study 19276664 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 181)
Number of subjects: 363
Study 17616769 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycemic-load diet
Number of subjects: 43
Study 17616769 — intervention group
Group type: COMPARATOR
Intervention: Control diet (carbohydrate-dense foods)
Number of subjects: 43
Study 15683145 — intervention group
Group type: EXPERIMENTAL
Intervention: 90-minute sleep-wake schedule (30 minutes in bed, 60 minutes awake) for 60 hours
Number of subjects: 35
Study 11779599 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human FSH (Gonal‐F)
Number of subjects: 0
Study 11779599 — intervention group
Group type: COMPARATOR
Intervention: Urinary FSH (Fertinex)
Number of subjects: 0
Study 9696002 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotherapy (Group 1)
Number of subjects: 72
Study 9696002 — intervention group
Group type: COMPARATOR
Intervention: Control (Group 2)
Number of subjects: 72
Study 7858335 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodiafiltration (Qb: 400 ml/min, Qd: 800 ml/min, time: 3.5 hours, 10 L hemofiltrate exchanges with Ringer's lactate or combination of Ringer's solution and saline using polysulfone membrane dialyzer)
Number of subjects: 6
Study 7858335 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodiafiltration
Number of subjects: 6